ERBB2 and esophageal cancer: ErbB2 is a well-established therapeutic target whose overexpression occurs in various solid tumors, including—but not limited to—breast, gastric, ovarian, colon, bladder, lung, uterine cervix, head and neck, and esophageal cancers [27].